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Summary  Hepatitis  C  virus  (HCV)  is  a  major  pathogen  with  approximately  3%  of  the  world’s
population  (over  170  million)  infected.  Epidemiological  studies  have  shown  HCV  is  associated
with an  increased  risk  of  cardiovascular  and  cerebrovascular  mortality  as  well  as  peripheral
arterial disease.  This  is  despite  HCV  inducing  an  ostensibly  favourable  lipid  proﬁle  with  accom-
panying low  classical  risk  score  for  atherosclerosis  (AS).  We  discuss  possible  factors  involved
in the  aetiopathogenesis  of  atherosclerosis  in  chronic  HCV  and  hypothesise  that  an  important
mechanism  underlying  the  development  of  AS  is  the  presence  of  circulating  low-density  immune
complexes that  induce  an  inﬂammatory  response.  We  suggest  that  HCV  particles  may  be  induc-
ing an  antibody  response  to  lipoproteins  present  in  the  lipoviral  particles  and  sub-viral  particles
— a  concept  similar  to  the  more  general  ‘autoantibody’  response  to  modiﬁed  LDL.  After  viro-
logic cure  some  AS  risk  factors  will  recede  but  an  increase  in  serum  cholesterol  could  result  in
progression  of  early  atherosclerotic  lesions,  leaving  a  legacy  from  persistent  HCV  infection  that
has clinical  and  therapeutic  implications.
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therosclerosis  (AS)  is  the  underlying  cause  of  heart  attack,
schaemic  stroke  and  peripheral  vascular  disease  and  hence
s  a  leading  cause  of  morbidity  and  mortality.  Traditional
isk  factor  assessment  has  focused  on  parameters  identiﬁed
n  epidemiological  studies  such  as  the  Framingham  Heart
tudy  (FHS)  (age,  hypertension,  cholesterol,  family  history,
nd  cigarette  smoking).  However,  a  sizeable  minority  of
atients  suffering  from  atherosclerosis  do  not  harbour  the
lassical  risk  factors.  Other  predisposing  factors  appear  to
ontribute  to  the  disease  process  including  chronic  viral
nfections  [1—3].
Lifelong  exposure  to  raised  concentrations  of  low-density
ipoprotein  cholesterol  (LDL-C)  increases  cardiovascular
vent  rates  and  the  use  of  statin  therapy  as  an  adjunct
o  diet,  exercise,  and  smoking  cessation  has  proven  highly
ffective  in  reducing  the  population  burden  of  disease  asso-
iated  with  hyperlipidaemia  [4].  Conversely,  rare  inherited
onditions  such  as  hypobetalipoproteinemia  and  PCSK9  loss-
f-function  mutations  have  shown  that  very  low  LDL  levels
re  associated  with  reduced  risk  of  cardiovascular  disease
5].
The  human  hepacivirus,  hepatitis  C  virus  (HCV)  is  a
ajor  pathogen  with  approximately  3%  of  the  world’s  pop-
lation  (over  170  million)  infected.  70%  of  those  infected
ail  to  clear  the  virus  and  are  at  risk  of  developing  liver
omplications,  mainly  cirrhosis  and  liver  cancer.
HCV  affects  cholesterol  homeostasis  and  chronic  infec-
ion  is  associated  with  a  decrease  in  serum  concentrations
f  total  cholesterol,  LDL-C  and  apolipoprotein  B  (apoB  —
he  main  protein  constituent  of  LDL  and  very-low-density
ipoprotein  (VLDL)).  These  changes  are  more  marked  in
CV  genotype  3  infection  and  effective  anti-viral  treat-
ent  results  in  their  reversal  (reviewed  in  [6,7]).  Despite
his  apparently  favourable  lipid  proﬁle,  HCV  infection  is
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Table  1  Some  observational  studies  in  HCV  exposed  individuals  i
Reference  No.  of  participants  
Guiltinan  AM  et  al.,  2008  [19]  10,259  HCV  antibody-positive  (H
10,259  HCV  antibody-negative  (H
blood  donors
Butt AA  et  al.,  2009  [20]  82,083  HCV-infected  vs  89,582
HCV-uninfected  subjects
Freiberg MS  et  al.,  2011  [21]  8579  participants  (9%  HIV+HCV+  
HIV+ HCV−)
Lin MS  et  al.,  2014  [22]  5015  eligible  Taiwanese  resident
years
Pothineni  NV  et  al.,  2014  [23]  8251  HCV  antibody  positive,  143
positive,  vs  14,799  HCV  negative
Lee MH  et  al.2010  [25]  23,665  residents  (aged  30—65  ye
cerebrovascular  deaths  during  38
person-years  of  follow-up
Hsu YH  et  al.,  2015  [26]  7641  HCV-infected  patients  and  
matched  controls
Bold: signiﬁcant increased risk of AS.M.F.  Bassendine  et  al.
ssociated  with  an  increased  risk  of  atherosclerosis  and  its
linical  manifestations  [8].
CV and atherosclerosis
t  became  apparent  over  a  decade  ago  that  HCV  might  be
onsidered  as  a risk  factor  for  the  development  of  coronary
rtery  disease  (CAD)  [9]. In  2012,  a  systematic  review  of  the
iterature  suggested  an  increased  risk  of  CAD  in  HCV-infected
ndividuals  [10]. Subsequently  myocardial  perfusion  defects
ave  been  found  in  87%  of  the  patients  with  chronic  hepatitis
,  which  improved  with  viral  eradication  [11].
Carotid  intima-media  thickness  (IMT)  has  been  used  as
 surrogate  of  sub-clinical  atherosclerosis  and  studies  have
hown  that,  after  adjustment  for  classical  cardiovascular
isk  factors,  those  with  chronic  HCV  infection  have  raised
MT  [12]  and  this  occurs  at  an  earlier  age  [13]. HCV  RNA  has
een  found  in  carotid  plaques  [14].  Recent  meta-analyses
ave  shown  that  HCV  infection  increases  the  risk  of  devel-
ping  carotid  intima  media  thickening  by  approximately
-fold  [15];  other  studies  found  an  increased  risk  of  carotid
therosclerosis  and  of  stroke  (pooled  OR  of  1.76  &  1.97
espectively)  [16,17].
Although  some  of  the  earlier  studies  did  not  identify
n  association  between  HCV  and  cardiovascular  morbidity
reviewed  in  [18]),  an  increasing  number  of  large  epidemio-
ogical  studies  do  conﬁrm  an  association  of  HCV  infection
ith  atherosclerosis  [19—22]  (Table  1).  One  recent  ret-
ospective  cohort  study  found  that  both  HCV  antibody
ositivity  (n  =  8251  individuals)  and  HCV  RNA  positivity  (1434
ndividuals)  were  independent  risk  factors  for  coronary  heart
isease  events  (OR  1.32  and  1.59  respectively),  when  com-
ared  to  14,799  HCV  negative  patients  [23]. This  study
oncluded  that  lipid  proﬁle  did  not  appear  to  be  a  good  car-
iovascular  disease  risk  stratiﬁcation  tool  in  patients  with
CV  infection.  Another  recent  study  has  also  concluded  that
dentifying  risk  of  AS.
Atherosclerosis  risk
CV+)  vs
CV−)
Increase  in  cardiovascular  mortality
(HR  =  2.21,  95%  CI:  1.41—3.46)
Higher  risk  of  CAD  (HR  =  1.25,  95%  CI:
1.20—1.30).
vs  28% HIV+HCV+  had  higher  risk  of  CHD  (HR  =  2.03,
95% CI:  1.28—3.21)
s,  age  >40 HCV+  had  1.76-fold  risk  of  ischaemic  ECG
when  compared  with  non-HCV
4  HCV  RNA
 patients
Increased  risk  of  incident  CHD  events  in  HCV
antibody-positive  (OR  =  1.32,  95%  CI:
1.09—1.60,  P  <  0.001)  and  HCV  RNA  positive
(OR =  1.59,  95%  CI:  1.13—2.26,  P  <  0.001)
ars),  255
2,011
Increase  in  cerebrovascular  death  (HR  =  2.18,
95%  CI:  1.50—3.16)  for  HCV-antibody  positive
30,564 Increase  in  peripheral  arterial  disease  in
HCV-infected  patients  (HR  =  1.43,  95%  CI:
1.23—1.67)  compared  with  non-HCV  patients
••
•HCV  and  atherosclerosis:  a  legacy  after  virologic  cure?  
the  Framingham  Risk  Score  (FRS)  may  underestimate  coro-
nary  heart  disease  (CHD)  risk  in  both  HCV  mono-infected  and
HIV/HCV  co-infected  persons  [24].
In  a  community  based  prospective  cohort  study  of  23,665
Taiwanese  residents  (aged  30—65  years)  the  hazard  ratio
of  cerebrovascular  death  was  2.18  (95%  CI:  1.50—3.16)  for
anti-HCV  seropositive  individuals  after  adjustment  for  con-
ventional  risk  factors  of  cerebrovascular  disease.  Compared
with  participants  seronegative  for  anti-HCV  as  the  refer-
ent,  the  multivariate-adjusted  hazard  ratio  was  1.40,  2.36
and  2.82,  respectively,  for  anti-HCV-seropositive  partici-
pants  with  undetectable,  low,  and  high  serum  levels  of  HCV
RNA  (P  <  0.001  for  trend)  [25].
Another  manifestation  of  atherosclerosis  is  peripheral
vascular  disease  and,  again,  a  population  based  study  in
Taiwan  of  7641  HCV-infected  patients  compared  to  30,564
matched  controls  has  found  a  higher  adjusted  risk  of  periph-
eral  arterial  disease  in  the  HCV-infected  group  of  1.43  which
increased  with  age  to  11.7  in  those  aged  65  years  and  above
[26].
Aetiopathogenesis of HCV-associated
atherosclerosis
As  elevated  LDL-C  does  not  play  a  role  during  persistent  HCV
infection  and  FRS  underestimates  AS  risk  in  these  patients,
it  is  important  to  examine  other  factors  that  may  be  play-
ing  a  role.  HCV  infection  may  represent  a  new  paradigm
and  reveal  mechanism(s)  that  are  relevant  in  up  to  20%  of
patients  with  coronary  heart  disease  who  do  not  have  con-
ventional  risk  factors  [27].
It  is  likely  that  the  aetiopathogenesis  of  AS  in  HCV  infec-
tion  is  multifactorial  and  pathogenic  mechanism(s)  may
include:
•  Endothelial  dysfunction:  in  the  last  decades  the  endothe-
lium  has  emerged  as  the  key  regulator  of  vascular
homeostasis.  Endothelial  dysfunction  and  inﬂammation
are  linked  to  the  pathogenesis  of  atherosclerotic  disease.
Increased  risk  for  CV  events  is  associated  with  increased
levels  of  cytokines,  cell-adhesion  molecules,  P-selectin
and  E-selectin  and  acute  phase  reactants,  such  a  high-
sensitivity  C-reactive  protein  (CRP).  Platelet-endothelial
interactions  occur  in  early  atherosclerosis.  Soluble  P-
selectin,  a  marker  of  in  vivo  platelet  activation,  is  a
cellular  adhesion  molecule  that  has  been  shown  to  be  cru-
cial  in  development  of  CHD.  A  positive  linear  association
between  P-selectin  levels  and  rate  of  incident  CHD  after
adjustment  for  traditional  risk  factors  has  been  observed
[28].
HCV  infection  of  endothelial  cells  [29]  may  promote
endothelial  dysfunction  and  early  atherogenesis.  Patients
with  chronic  hepatitis  C  infection  have  increased  levels
of  several  inﬂammatory  markers  including  high-sensitivity
CRP,  soluble  intercellular  adhesion  molecule-1,  soluble
vascular  cell  adhesion  molecule-1,  soluble  E-selectin  and
P-selectin  [30,31].•  Lipid  disturbances:  HCV  causes  profound  changes  in
lipid  metabolism  including  a  raised  Cholesteryl  Ester
Transfer  Protein  (CETP)  [32].  CETP  promotes  the  trans-
fer  of  cholesteryl  esters  from  HDL  to  very-low-density27
lipoprotein  and  LDL.  Human  genetic  studies  and  human
cohort  studies  have  concluded  that  CETP  gene  poly-
morphisms  associated  with  decreased  CETP  activity  are
accompanied  by  a  signiﬁcantly  lower  risk  of  atheroscle-
rotic  cardiovascular  disease.
CETP  inhibition  raises  HDL-C  levels,  long  touted  as  the
‘‘good  cholesterol’’,  and  is  being  evaluated  for  treatment
of  atherosclerosis  [33].  CETP  inhibitors,  as  monotherapy
or  with  statins,  signiﬁcantly  reduce  the  concentrations  of
atherogenic  apoB-containing  lipoproteins,  including  Lp(a)
[34].  However  recent  phase  3  outcome  trials  have  shown
limited  beneﬁt  of  CETP  inhibitors  on  cardiovascular  out-
comes  when  combined  with  the  current  standard  of  care
[35].  Hence  no  one  CETP  inhibitor  is  currently  available
in  the  clinic.  Future  trials  should  possibly  focus  on  indi-
viduals  with  both  AS  and  raised  CETP  such  as  those  with
chronic  HCV  infection.
 Metabolic  disturbances:  positive  associations  have  been
observed  between  CVD  and  type  2  diabetes  mellitus  (DM),
but  their  causal  relationship  has  not  been  clariﬁed.  Epi-
demiological  data  indicate  a  risk  for  development  of
insulin  resistance  (IR)  particularly  in  patients  with  hep-
atitis  C  virus  (HCV)  genotype  1  infection  and,  ultimately,
overt  DM  [36], although  a  recent  large  population-based
study  has  not  conﬁrmed  an  appreciable  excess  risk  of  DM
[37].  However,  in  a  meta-analysis  of  22  observational  stud-
ies,  the  effect  of  HCV  on  CVD  mortality  was  stronger  in
populations  with  a  higher  prevalence  of  diabetes  (>10%)  or
hypertension  (>20%)  (OR,  1.71;  95%  CI:  1.32—2.23;  P  <  .001
for  both)  [38].  Eradication  of  HCV  improves  IR  and  insulin
hypersecretion,  as  well  as  high  baseline  insulin  resistance
(HOMA-IR  >  2.5)  [39],  so  this  risk  factor  should  resolve
after  virologic  cure.
 MicroRNAs  (miRNAs)  are  small  noncoding  RNAs  involved
in  intercellular  communication;  they  have  been  shown  to
circulate  in  the  bloodstream  in  stable  forms.  In  the  past
years  speciﬁc  miRNA  expression  patterns  have  been  linked
to  the  development  of  atherosclerosis  [40].  HCV  infection
alters  the  expression  of  host  miRNAs  and,  in  turn,  miRNAs
are  able  to  regulate  HCV  replication  [41].  It  has  been  pro-
posed  that  miR-122,  the  most  abundant  liver  miRNA  which
plays  a  central  role  in  the  maintenance  of  lipid  homeosta-
sis,  may  constitute  a  novel  biomarker  for  cardiovascular
disease  [42].
MiR-122  has  been  shown  to  modulate  hepatic  pro-
duction  of  apoB-containing  low  density  lipoprotein  [43]
and  is  a  sensitive  serum  marker  to  distinguish  chronic
hepatitis  C  patients  from  healthy  controls  [44]. Admin-
istration  of  miravirsen,  an  anti-miR-122  oligonucleotide,
has  been  shown  to  result  in  a  dose  dependent  and  pro-
longed  decrease  in  HCV  RNA  levels  in  chronic  hepatitis  C
patients  [45]. The  role  of  the  deranged  miRNAs  induced
by  HCV  in  the  aetiopathogenesis  of  HCV-associated  AS  is
unclear.
 Autoimmunity:  (auto)immune  reactivity  to  a  range  of
autoantigens,  but  most  prominently  modiﬁed  LDL  (mLDL),
is  a  marker  of  human  cardiovascular  disease  and  in  exper-
imental  models  plays  a  signiﬁcant  role  in  promoting
atherosclerotic  plaque  progression.  Both  pathogenic  and
protective  immunity  to  apoB  have  been  identiﬁed  [46]  but
it  appears  that,  in  humans,  the  humoral  immune  response
to  mLDL  is  pathogenic  rather  than  protective[reviewed  in
28  M.F.  Bassendine  et  al.
Figure  1  (Auto)immune  reactivity  to  a  host  antigen(s)  within  HCV  lipo-viral  and  sub-viral  particles  may  play  a  role  in  promoting
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[47]].  B  cell-activating  factor  (BAFF)  is  a  tumour  necrosis
factor-family  cytokine  that  plays  a  key  role  in  generating
and  maintaining  the  mature  B-cell  pool.  BAFF  is  known  to
be  involved  in  the  occurrence  of  autoimmune  diseases.
BAFF  signalling  via  the  B-cell  activating  factor  receptor
(BAFFR)  is  essential  for  B2  cell  survival;  these  cells  seem
to  be  proatherogenic.  In  chronic  HCV  infection,  elevation
in  serum  BAFF  has  been  reported  to  be  associated  with
HCV-related  vasculitis  (P  <  0.0001),  and  with  the  pres-
ence  of  anticardiolipin  antibodies  and  of  cryoglobulins
[48].
Modiﬁed  LDL-containing  immune  complexes  (mLDL-IC)
play  a  role  in  the  formation  of  early  atherosclerotic
lesions  (reviewed  in  [49,50]).  Infectious  HCV  lipoviral
particles  (LVPs)  found  in  the  low  density  fraction  of
blood  contain  HCV-RNA  +  structural  viral  proteins  +  apoB  +
apoE  +  apoCII  +  triglycerides  +  cholesterol  +  phospholipids;
the  majority  are  complexed  with  IgG  and  IgM  [51].
However  it  is  now  clear  that  LVPs  are  a  mixed  population
of  particles,  comprising  predominantly  subviral  particles
which  outnumber  HCV-RNA  containing  LVPs  by  >1  ×  106.
These  HCV  envelope  glycoprotein-positive  lipoproteins
represent  a  distinct  class  of  modiﬁed  lipoproteins  within
the  TRL  family  [52]  and  are  present  in  immune-complexes
in  patients  with  chronic  HCV.  We  hypothesise  that  an
important  mechanism  underlying  the  development  of
AS  in  HCV  infection  is  the  presence  of  these  circulat-
ing  low-density  immune  complexes  that  are  taken  up
by  monocytes  via  Fc  gamma  receptors,  inducing  an
inﬂammatory  response  (Fig.  1).  HCV  has  been  found  in
n
c
ecutaneous  vasculitic  lesions  in  complex  with  IgM  and  IgG
in  patients  with  type  II  cryoglobulinemia  [53].
Atherosclerosis  initiation  and  progression  are  thought
to  be  primarily  mediated  by  cells  of  the  mono-
cyte/macrophage  lineage  [54,55].  The  uptake  of  mLDL-
immune  complexes  by  human  macrophages  leads  to
massive  cholesterol  ester  accumulation,  cytokine  release
and  overexpression  of  the  LDL  receptor  (LDLR)  [56]. LDLR
plays  a  role  in  the  life-cycle  of  HCV  [57]  and  HCV  infection
induces  higher  expression  of  LDLR  on  lymphocytes  and
monocytes  [58].  Monocytes,  macrophages  and  dendritic
cells  can  be  infected  by  HCV,  so  a  direct  pro-inﬂammatory
effect  may  also  contribute  to  AS.  In  addition  HCV  infec-
tion  of  monocytes  increases  immunoregulatory  galectin-9
production  and  there  is  emerging  evidence  for  a  role  for
galectins  in  AS  [59].
irologic cure and atherosclerosis
irologic  cure  is  now  achievable  in  the  vast  majority  of
atients  treated  with  direct-acting  anti-viral  (DAA)  therapy
nd  reduces  the  risk  of  liver  disease  progression  [60].
The  effect  of  virologic  cure  on  AS  progression  is  however
nknown  but  a signiﬁcant  AS  risk  has  also  been  reported
n  those  that  are  HCV  antibody  positive  but  HCV  RNA
egative.
Early  atherosclerotic  lesions  appear  to  be  a  feature  of
hronic  HCV  infection,  despite  the  virus  inducing  an  appar-
ntly  favourable  lipid  proﬁle.  AS  risk  increases  with  age  and
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therefore,  presumably,  duration  of  chronic  viral  infection.
Current  evidence  indicates  that  the  risk  of  a  person  with
chronic  hepatitis  C  developing  coronary  atherosclerosis  is
about  triple  the  risk  in  uninfected  persons  (OR  = 3.06,  95%
CI  =  1.99—4.72)  [61].  Virologic  cure  will  be  lead  to  improve-
ments  in  some  AS  risk  factors  outlined  above  such  as  insulin
resistance  [39]  and  the  consequences  of  direct  infection
of  endothelial  cells  and  monocytes  but  others  factors  such
as  HCV-induced  autoimmunity  to  mLDL  may  persist.  This  is
suggested  by  the  observation  in  chimpanzees  that  the  fre-
quency  of  T-regulatory  cells  and  the  extent  of  suppression
is  as  high  in  those  that  recovered  from  HCV  as  in  persis-
tently  HCV-infected  animals,  suggesting  ongoing  control  of
an  ‘autoimmune’  response  [62].
In  addition  virologic  cure  will  result  in  increases  in  serum
cholesterol  and  LDL-C  [63],  creating  a  combination  of  cir-
cumstances  that  will  aggravate  early  atherosclerotic  lesions.
This  ‘perfect  storm’  for  AS  progression  after  virologic  cure
has  important  clinical  and  therapeutic  implications.  Not
only  should  patients  be  monitored  for  AS  but  statin  ther-
apy  should  also  be  considered.  This  is  particularly  pertinent
if  an  autoimmune  response  to  mLDL  persists  after  cure  as
a  recent  study  has  shown  that  simvastatin  therapy  in  CAD
patients  lowers  small  LDL-IgG-IC  levels  to  a  greater  extent
than  LDL-cholesterol  levels  [64].
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